Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Flex Pharma Seals Financing
by Lisa M. Jarvis
September 15, 2014
| A version of this story appeared in
Volume 92, Issue 37
Boston-based Flex Pharma has secured $40 million in financing from a wide range of public and private investors. The months-old biotech firm is focused on developing drugs to treat muscle cramps and spasms using technology developed by its scientific cofounder, Roderick MacKinnon, who won the 2003 Nobel Prize in Chemistry for his work on ion channels. Flex Pharma is led by Christoph Westphal, who previously started Sirtris, a biotech firm sold to GlaxoSmithKline in 2008 for $720 million; last year GSK shut the unit down.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X